Search & Analyze

Emcure Pharmaceuticals Ltd.

HealthcarePharmaceuticals & Drugs

www.emcure.com BSE: 544210NSE: EMCURE

₹1,929.05BSE3.89%

16 Sep, 4:01 PM

₹1,929.05

₹36.66K Cr

36.24

7.01

20.09%

₹2,014.55

₹1,903.70

₹2,047.40

₹1,260.10

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Emcure Pharmaceuticals Ltd. EMCURE	1,929.05	36.24	36,656.84	0.19	292.49	36.17%	2,580.45	22.85%	25.25

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,815.14	2,001.98	1,962.63	2,116.25	2,100.54	2,269.82	2,363.48	2,469.70	2,580.45
Expenses	1,478.47	1,621.29	1,608.02	1,713.85	1,683.76	1,830.70	1,870.73	1,990.15	2,047.95
	336.67	380.70	354.61	402.40	416.77	439.13	492.74	479.55	532.50
	18.55%	19.02%	18.07%	19.01%	19.84%	19.35%	20.85%	19.42%	20.64%
	23.08	35.83	3.90	-5.93	0.20	39.48	-36.30	14.29	2.07
Interest	58.76	46.22	31.78	39.03	26.76	32.54	37.98	46.40	31.54
	93.59	96.90	96.81	96.84	99.46	104.64	104.68	106.27	109.51
	207.41	273.41	229.92	260.61	290.76	341.42	313.79	341.18	393.53
	26.43%	26.28%	32.11%	24.32%	26.13%	26.37%	26.27%	28.56%	25.67%
	144.08	194.57	153.72	188.96	206.95	243.46	230.54	243.40	293.98
	7.95	10.29	8.11	9.97	10.92	12.84	12.16	12.84	15.50

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	5,979.37	6,097.79	6,786.12	8,022.86	9,394.13
	5,855.39	5,985.81	6,658.25	7,896.00	9,203.54
EXPENDITURE :
Increase/Decrease in Stock	-145.40	66.69	-190.19	-263.53	-432.96
Raw Material Consumed	2,172.59	2,004.40	2,446.98	3,172.52	3,829.11
Power & Fuel Cost	97.28	108.58	120.04	138.00	135.64
Employee Cost	1,011.82	1,117.33	1,292.08	1,446.29	1,552.20
Other Manufacturing Expenses	477.71	451.11	504.61	589.22	704.78
General and Administration Expenses	372.10	484.31	545.89	562.29	617.79
Selling and Distribution Expenses	397.36	414.52	516.58	592.77	746.07
Miscellaneous Expenses	142.01	157.68	192.53	189.59	305.18
	4,525.48	4,804.63	5,428.53	6,427.14	7,457.80
Operating Profit (Excl OI)	1,329.91	1,181.18	1,229.72	1,468.85	1,745.74
	63.47	45.91	56.99	72.79	131.47
	1,393.38	1,227.09	1,286.71	1,541.64	1,877.21
Interest	175.98	213.61	237.15	175.78	143.67
PBDT	1,217.40	1,013.48	1,049.57	1,365.86	1,733.54
	244.86	260.12	312.41	384.13	415.05
Profit Before Taxation & Exceptional Items	972.55	753.36	737.16	981.73	1,318.49
Exceptional Income / Expenses		-6.15	-9.93	-10.38	-31.35
	972.55	747.22	727.23	971.35	1,287.14
Provision for Tax	269.99	185.37	199.65	263.88	345.87
	702.56	561.85	527.58	707.47	941.27
Extra items				0.00	0.00
Minority Interest	-40.36	-29.83	-29.39	-26.14	-16.91
Consolidated Net Profit	662.20	532.02	498.18	681.33	924.36
Profit Balance B/F	1,743.97	1,695.31	2,196.42	2,634.01	3,312.95
Appropriations	2,406.17	2,227.33	2,694.61	3,315.34	4,237.31
Equity Dividend %	30.00%	20.00%	30.00%	30.00%	36.00%
	36.62	29.42	27.50	35.96	48.76
Adjusted EPS	36.62	29.42	27.50	35.96	48.76

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	180.85	180.85	181.15	189.48	189.59
Share Warrants & Outstandings	15.92	14.85	14.50	11.86	11.99
Total Reserves	1,790.78	2,305.42	2,756.63	4,244.84	4,748.45
Reserve excluding Revaluation Reserve	1,790.78	2,305.42	2,756.63	4,244.84	4,748.45
Revaluation reserve	0.00	0.00		0.00
	1,987.55	2,501.13	2,952.28	4,446.19	4,950.03
Minority Interest	126.59	148.53	169.48	195.37	26.64
Secured Loans	708.74	737.23	761.36	186.41	250.42
Unsecured Loans	8.54	6.90	5.24	3.53	1.79
Deferred Tax Assets / Liabilities	-73.47	-60.23	40.63	9.04	-41.37
Other Long Term Liabilities	182.50	180.98	526.59	565.35	330.76
Long Term Provisions	42.11	39.67	43.32	47.58	42.60
Total Non-Current Liabilities	868.42	904.55	1,377.13	811.91	584.19
Trade Payables	1,125.19	1,086.11	1,309.37	1,479.58	1,807.77
Other Current Liabilities	649.03	712.22	854.77	547.25	1,093.72
Short Term Borrowings	1,084.60	1,132.00	947.16	474.62	795.49
Short Term Provisions	106.01	88.87	99.18	166.82	215.26
Total Current Liabilities	2,964.83	3,019.19	3,210.47	2,668.27	3,912.24
Total Liabilities	5,947.39	6,573.41	7,709.37	8,121.73	9,473.11
Gross Block	3,471.97	3,802.48	5,092.12	5,437.89	6,005.10
Less: Accumulated Depreciation	1,427.66	1,655.59	1,967.57	2,241.16	2,685.89
Net Block	2,044.31	2,146.89	3,124.55	3,196.73	3,319.22
Capital Work in Progress	309.80	403.53	132.35	124.06	172.06
Non Current Investments	25.00	25.00	18.42	19.34	19.70
Long Term Investment	25.00	25.00	18.42	19.34	19.70
Long Term Loans & Advances	111.65	114.30	143.62	160.75	235.80
Other Non Current Assets	22.43	39.89	3.75	11.65	13.58
Total Non-Current Assets	2,523.29	2,737.49	3,449.45	3,565.87	3,861.01
Currents Investments			299.65	76.04
Inventories	1,449.42	1,383.03	1,525.10	1,931.81	2,397.87
Sundry Debtors	1,308.51	1,648.30	1,858.81	2,002.24	2,562.66
Cash and Bank	313.30	458.26	232.41	165.30	147.52
Other Current Assets	86.35	78.79	99.39	85.13	105.42
Short Term Loans and Advances	266.54	267.54	239.14	295.34	398.63
Total Current Assets	3,424.10	3,835.91	4,254.49	4,555.86	5,612.10
Net Current Assets (Including Current Investments)	459.27	816.72	1,044.02	1,887.59	1,699.86
Total Assets	5,947.39	6,573.41	7,709.37	8,121.73	9,473.11
Contingent Liabilities	12.07	96.95	285.51	393.94	258.92
Total Debt	2,077.27	2,181.61	2,072.49	731.70	1,204.08
	109.02	137.48	162.17	234.02	260.46
Adjusted Book Value	109.02	137.48	162.17	234.02	260.46

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	972.55	747.22	727.23	971.35	1,287.14
Adjustment	398.74	492.35	543.15	551.51	554.62
Changes In working Capital	-291.91	-292.24	50.52	-424.30	-530.13
Cash Flow after changes in Working Capital	1,079.38	947.33	1,320.89	1,098.56	1,311.63
Cash Flow from Operating Activities	768.21	746.85	1,097.24	851.70	943.55
Cash Flow from Investing Activities	-788.79	-467.69	-712.51	-94.00	-1,193.06
Cash Flow from Financing Activitie	-151.85	-145.40	-164.21	-813.96	343.43
Net Cash Inflow / Outflow	-172.44	133.77	220.52	-56.25	93.92
Opening Cash & Cash Equivalents	-350.04	-308.17	-174.53	43.99	-14.31
Cash & Cash Equivalent on Amalgamation / Take over / Merger	214.12
Effect of Foreign Exchange Fluctuations	0.19	-0.13	-2.00	-2.05	18.16
Closing Cash & Cash Equivalent	-308.17	-174.53	43.99	-14.31	97.77

Ratios

Valuation

36.24

7.01

18.94

3.79

53.31

275.72

Profitability

20.09

25.25

10.70

18.58

10.02

Leverage & Liquidity

0.24

1.43

9.96

Returns

0.19

1.07

Shareholding Pattern

Numbers in percentages

Particulars	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	78.08	77.94	77.92	77.91	77.88	77.87	77.87	77.83
	6.87	6.92	6.51	5.70	7.66	9.69	9.46	13.34
	15.05	15.14	15.57	16.39	14.46	12.44	12.69	8.83
	21.92	22.06	22.08	22.09	22.12	22.13	22.13	22.17
No. of Shareholders	1,52,914	1,43,449	1,39,671	1,33,549	1,26,169	1,18,863	1,22,189	1,24,991

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-08-31	AGM
2026-07-15	Board Meeting	Quarterly Results
2026-05-05	Ex Dividend	Rs.3.6000 per share(36%)Final Dividend	2026-09-04	2026-09-04

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Emcure Pharmaceuticals Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

12 members across the board and senior leadership

Berjis Desai

Chairman

₹1.46 Cr

Mar '26

Satish Mehta

Managing Director & Chief Executive Officer

₹32.40 Cr

Mar '26

Sunil Mehta

Whole Time Director

₹5.08 Cr

Mar '26

Mukund Gurjar

Whole Time Director

₹6.53 Cr

Mar '26

Namita Thapar

Whole Time Director

₹4.98 Cr

Mar '26

Samit Satish Mehta

Whole Time Director

₹3.51 Cr

Mar '26

Vijay Gokhale

Non Executive Independent Director

₹28.00 L

Mar '26

Shailesh Ayyangar

Non Executive Independent Director

₹78.60 L

Mar '26

Vidya Yeravdekar

Non Executive Independent Director

₹21.60 L

Mar '26

CS Muralidharan

Non Executive Independent Director

—

Amruta Yangalwar

Company Secretary & Compliance Officer

—

Amruta Jana Yangalwar

Company Secretary and Compliance Officer

—

EMCURE Latest News

News

10 of 10 articles

EQUITY10 Aug 2026 · 12:07

Emcure Pharmaceuticals moves up on getting EIR from USFDA for Sanand facility

The USFDA conducted this inspection from May 06, 2026 to May 15, 2026

COMPANY10 Aug 2026 · 11:48

Emcure Pharmaceuticals gets EIR from USFDA for Sanand facility

The USFDA conducted this inspection from May 06, 2026 to May 15, 2026

EQUITY21 Jul 2026 · 15:02

Emcure soars on getting nod to market Poviztra for treatment of non-cirrhotic MASH

The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease

COMPANY21 Jul 2026 · 14:27

Emcure gets nod to market Poviztra for treatment of non-cirrhotic MASH

The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease

EQUITY14 Jul 2026 · 11:40

Emcure Pharmaceuticals rises on inking pact to acquire remaining 12.05% stake in Gennova

The Gennova will become a wholly-owned subsidiary of the company after completion of the transaction

COMPANY14 Jul 2026 · 11:27

Emcure Pharmaceuticals to acquire remaining 12.05% stake in Gennova

The Gennova will become a wholly-owned subsidiary of the company after completion of the transaction

EQUITY3 Jul 2026 · 11:47

Emcure Pharmaceuticals informs about acquisition

EQUITY12 Jun 2026 · 10:12

Emcure Pharmaceuticals informs about investor presentation

COMPANY10 Jun 2026 · 13:05

Kotak Mahindra Mutual Fund buys stake worth Rs 612 crore in Emcure Pharmaceuticals

Kotak Mahindra Mutual Fund has bought 36 lakh equity shares at price of Rs 1,700 apiece

COMPANY16 May 2026 · 18:25

USFDA concludes cGMP inspection at Emcure Pharmaceuticals’ Gujarat facility

At the conclusion of the inspection, the company was issued a Form 483 with 7 observation(s)

EMCURE

₹1,929.05

-3.89%